Suzhou Basecare Medical (HKG:2170) forecasts revenue to increase between 42% to 47% to between 295 million yuan and 305 million yuan in 2024 from 208 million yuan in 2023, according to a Monday filing with the Hong Kong Exchange.
The foreseen rise in revenue is attributable to higher sales following the purchase of BMX Holdco, as well as other sales and purchase agreements for reproductive health products, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。